Accumulate shares of Intel (INTC) during post-earnings volatility, as the market is offering a strong long-term buying opportunity despite solid fundamentals. Treat recent weakness in mega-cap leaders like Alphabet (GOOGL) as an attractive accumulation phase for patient, long-term investors. Capitalize on high-volume intraday momentum shifts in memory plays like Micron Technology (MU), while preparing for extreme volatility and beta. Avoid volatile consumer health stocks like Hims & Hers Health (HIMS) due to growing market skepticism surrounding peripheral peptide product expansions. Maintain a cautious stance on Broadcom (AVGO) as a potential short candidate due to emerging competitive threats from rivals taking custom silicon market share.

Intel (INTC)

• Despite reporting a "pretty much perfect quarter" where they beat earnings expectations by roughly $2 billion, raised guidance above Wall Street estimates, and had their foundry business on track, the stock experienced high volatility, dropping significantly after initial excitement (trading down around 6% to 9% by the end of the session).
• Martin Shkreli initially shorted the stock but covered, went long, and maintained a bullish stance, calling Intel a "mandatory" buy down at lower levels (mentioning price points like $96 and noting it as a great long-term opportunity).
• Risk Factors: High expectations going into the quarter caused the stock to become overheated; the speaker noted that even with an exceptional quarter, the market reacted with heavy selling and risk-off behavior.

Takeaways

• Look for buying opportunities on over-reactions when fundamentally strong companies with stellar quarters get dragged down by broader market sell-offs.
• Actionable Insight: The speaker considers Intel a strong long-term buy despite short-term downward pressure and volatility.

Google / Alphabet (GOOGL)

• Has faced downward pressure for roughly six months.
• The stock saw a very meager bounce initially during the session, described as "basically no bounce at all," though it later showed signs of life with a "violent" and beautiful upward move relative to the rest of the struggling tech sector.
• The company reported record revenue and large spending, which the speaker views as fundamentally strong for the ecosystem, even if the market reacted with initial nervousness.

Takeaways

• Google is viewed as a high-conviction long-term hold alongside tech giants like Microsoft and Berkshire Hathaway ("stocks that matter").
• Actionable Insight: Patient investors should view meager bounces or weakness in high-performing mega-caps as accumulation phases rather than exit signals.

Micron Technology (MU)

• Experienced heavy trading volume (with $1.5 billion to $24 billion traded depending on the metric) and high volatility, ultimately getting "smoked" down to around the $950-$960 level.
• The stock saw a wild, quick rally at the very end of the trading day (bouncing roughly 1% in a minute or two).
• Bearish Sentiment: Mentioned that some market participants remain bearish on memory chips, though the speaker aggressively plays the liquidity ("I said buy a million micron").

Takeaways

• High-volume tech and memory plays like Micron offer rapid intraday swings that require active management.
• Actionable Insight: Capitalize on end-of-day momentum shifts, but expect extreme beta and volatility in memory-related semiconductor stocks.

Hims & Hers Health (HIMS)

• Dropped significantly (down 9% to 10% on the day).
• The drop was driven by disappointment surrounding the company's peptide business/meeting, which the speaker openly criticized as a "stupid peptide bullshit thing" and a "scam."

Takeaways

• Risk Factors: Regulatory or market skepticism regarding peripheral product expansions (such as peptides) can severely impact sentiment and share price in consumer health/telehealth companies.
• Actionable Insight: Avoid companies attempting to chase crowded or questionable market trends (like peptide offerings) if core growth narrative loses credibility.

Spruce Biosciences (SPRU)

• The speaker remains extremely bullish on the stock, viewing it as a long-term $400 or $500 stock.
• Price fluctuations and small dips do not alter the speaker's long-term thesis because of deep expertise in rare diseases ("I know rare diseases like the back of my hand").

Takeaways

• Actionable Insight: Maintain conviction in niche biotech/rare disease plays based on fundamental pipeline knowledge rather than emotional reactions to minor price drops. The speaker recommends holding or adding to the position.

Broadcom (AVGO)

• The speaker holds a bearish sentiment on Broadcom, stating it is a short candidate.
• Risk Factors: Business is reportedly shifting away from Broadcom, with competitors like MediaTek taking market share and winning TPU deals (despite existing partnerships with OpenAI and Meta).

Takeaways

• Actionable Insight: Be cautious of hardware/chip giants facing emerging competitive threats in custom silicon and AI accelerators, as high expectations leave little room for error.

SpaceX (Private)

• Continues a slow descent/bleed into double digits on light-to-moderate volume (e.g., $200 million traded).
• The speaker believes the private stock "won't bottom for a while" and continues to drop.

Takeaways

• Actionable Insight: Patience is required for high-flying private or pre-IPO tech assets experiencing a correction phase; do not attempt to catch a falling knife too early.